Disease · HP_0006986
Upper limb spasticity
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Upper limb spasticity. Diseases, record HP_0006986. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0006986
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Upper limb spasticity
- Open Targets ID
- HP_0006986
- Other names
Spastic upper extremities, Spastic upper extremity, Spastic upper limb, Spastic upper limbs, Spasticity in upper extremities, Spasticity in upper extremity, Spasticity in upper limb, Spasticity in upper limbs, Spasticity of upper extremities, Spasticity of upper extremity, Spasticity of upper limb, Spasticity of upper limbs, Uncontrollable movement in upper arms, Upper extremities spasticity, Upper extremity spasticity
- Highest stage of its drugs
- Phase 3, for 4 of its 7 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 14 | 14 | 8 | Drugs and targets |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 12 | 12 | 5 | Drugs and targets | |
| LETIBOTULINUMTOXINA | CHEMBL3707322 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets | |
| INCOBOTULINUMTOXINA | CHEMBL2108035 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| RIMABOTULINUMTOXINB | CHEMBL1201569 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DAXIBOTULINUMTOXINA | CHEMBL3707359 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| GADOLINIUM | CHEMBL1232993 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SNAP25 | Synaptosomal-associated protein 25 | 5 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| VAMP2 | Vesicle-associated membrane protein 2 | 1 | Vesicle-associated membrane protein 2 inhibitor | Phase 2/3 | https://conductscience.org/library/genes/6844 | Drugs and targets |
Trials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 8 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01603602 | BOTOX® Treatment in Pediatric Upper Limb Spasticity | Phase 3 | 235 | 2018-08-14 | Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT01603615 | BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity | Phase 3 | 220 | 2019-08-21 | Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT00465738 | IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity | Phase 3 | 216 | 2010-12-06 | Upper Limb Spasticity | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT02106351 | Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children | Phase 3 | 212 | 2019-12-24 | Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT01153815 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity | Phase 3 | 170 | 2012-05-17 | Cerebrovascular Accident | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT00460564 | Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity | Phase 3 | 109 | 2010-02-10 | Post-Stroke Spasticity, Cerebrovascular Accident | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
| NCT01387074 | Observational Study of Botox® Treatment for Patients With Upper Limb Adult Spasticity | 108 | 2014-02-03 | Muscle Spasticity | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov | |
| NCT03821402 | Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity | Phase 2 | 83 | 2023-09-21 | Upper Limb Spasticity | DAXIBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT02145676 | OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity | Phase 3 | 53 | 2017-02-14 | Muscle Spasticity, Stroke | ONABOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT07478822 | A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity | Phase 3 | 300 | Upper Limb Spasticity | BOTULINUM TOXIN TYPE A | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials39
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: serious adverse events | 6 of 96 | 6 of 96 | 192 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Toilet Use | 7 of 94 | 6 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Bathing/Showering | 1 of 94 | 7 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Toilet Use | 11 of 94 | 7 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Grooming | 7 of 94 | 10 of 95 | 189 | NCT00465738 | Trial comparisons |
| incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Responder in FAT at Week 12 - Full Analysis Set | 20 of 94 | 22 of 95 | 189 | NCT00465738 | Trial comparisons |
| incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Responder in DAS at Week 4 - Full Analysis Set | 59 of 94 | 49 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Feeding | 8 of 94 | 6 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 4 - Item Dressing | 9 of 94 | 6 of 95 | 189 | NCT00465738 | Trial comparisons |
incobotulinumtoxinA (Xeomin) High-volume Dilution 20 Units/mL vs incobotulinumtoxinA (Xeomin) Low-volume Dilution 50 Units/mL: Response Rates in Activity of Daily Living (Barthel Index) at Week 12 - Item Bathing/Showering | 4 of 94 | 6 of 95 | 189 | NCT00465738 | Trial comparisons |
1 to 10 of 39
See all 39 comparisons in its trialsPapers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0006986
GET https://conductscience.org/api/diseases/v1/HP_0006986/comparisons?page=2